Hybrigenics Meets with EMEA on Further Clinical Development of inecalcitol
News Nov 18, 2009
Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announces its meeting with the European Medicines Agency (EMEA) in London to launch the formal process for official scientific advice on the clinical efficacy plan for inecalcitol in hormone-refractory prostate cancer patients.
Hybrigenics has outlined the design of a Phase IIb clinical trial of high doses of oral inecalcitol in addition to intravenous cycles of Taxotere®. The objective of the trial is to achieve "proof-of-concept" (PoC) based on the proportion of patients who will experience a decline in prostate specific antigen (PSA) under treatment.
The high response rate (87 percent) currently observed among patients in the ongoing Phase IIa dose-escalation tolerance study of inecalcitol provided the foundation for the proposed PoC.
The meeting with the EMEA marks the official start to the procedure of obtaining scientific advice on the technical aspects of study protocol. This will result in recommendations from the EMEA within approximately three months.
"Both the pre-IND meeting with the United States Food and Drug Administration (FDA) in the Spring, and now this pre-submission meeting with the EMEA, aim at putting inecalcitol on good regulatory tracks for further development," commented Remi Delansorne, Hybrigenics' CEO.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018